Concordia International announced that, it signed a three-year agreement with RedHill Biopharma to expand sales of Donnatal, the company's product used in the treatment of irritable bowel syndrome. Under the terms, RedHill intends to increase the promotion of Donnatal among U.S. doctors and marketing efforts are expected to begin in first quarter. It plans to promote the product in up to 30 sales territories over the three years.

RedHill will incur the sales and marketing costs associated with promotional activities, while Concordia will provide materials and samples. The latter will keep all revenue up to a predetermined level of sales and only after reaching that predetermined level will revenue be shared between the company and RedHill.